Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ZSQR

Z Squared Inc

Apr 28 • 03:40PM ET

14.59

-0.61 -4.01 %

Financial • Capital Markets • USA • NASD

Today, 8:40 AMZ Squared names Michelle Burke Co-CEO alongside David Halabu and appoints Ryan Schadel CMO as it formally advances its AI infrastructure strategy

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.80	Insider Own	16.56%	Shs Outstand	5.75M	Perf Week	-2.28%
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	5.19M	Perf Month	36.61%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	7.47%	Short Float	-	Perf Quarter	9.70%
Income	-10.91M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-2.73%
Sales	1.36M	P/B	4.86	EPS next Y	-	ROA	-70.73%	Short Interest	-	Perf YTD	2.39%
Book/sh	3.00	P/C	-	EPS next 5Y	-	ROE	-96.83%	52W High	21.41 -31.85%	Perf Year	62.65%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	62.31% 40.22%	ROIC	-62.70%	52W Low	6.80 114.56%	Perf 3Y	-38.70%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-207.81%	Volatility	27.74% 13.49%	Perf 5Y	-92.67%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	50.41%	Oper. Margin	-956.94%	ATR (14)	1.81	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.16	Sales Y/Y TTM	-	Profit Margin	-800.38%	RSI (14)	57.28	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.16	EPS Q/Q	80.71%	SMA20	9.74%	Beta	-0.15	Target Price	80.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	17.88%	Rel Volume	3.33	Prev Close	15.20
Employees	6	LT Debt/Eq	0.01	Earnings	-	SMA200	7.02%	Avg Volume	56.64K	Price	14.59
IPO	Dec 17, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	179,461	Change	-4.01%

Today 08:35AM	Z Squared Announces Executive Leadership Appointments to Advance AI Infrastructure Strategy (PR Newswire)
Apr-27-26 11:31AM	Z Squared Provides Additional Information on Previously Disclosed Pro Rata Distribution (PR Newswire) -7.32%

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. It operates through the Biotechnology and Technology segments. The Biotechnology segment is involved in developing biotechnology product pipelines. The Technology segment relates to acquiring technology assets to support and enhance operational capabilities through advanced technologies. The company was founded in 2017 and is headquartered in Wexford, PA.

open in yahoo | open in reuters | open in marketwatch | open in google

ZSQR

Z Squared Inc

Upgrade your Finviz experience